Protein composition used in special diet formula food for treating sarcopenia syndrome as well as preparation method and application of protein composition

Abstract

The invention discloses a protein composition used in special diet formula food for sarcopenia syndrome, a preparation method and application, and belongs to the field of food formulas for special diets. The protein composition comprises intact protein, protein hydrolysate and free amino acid, the content of leucine is 10 wt% or above, the total content of arginine and glycine is 5 wt% or above, the content of essential amino acid is 40 wt% or above, and the ratio of the intact protein to the protein hydrolysate is 80.7%: 19.3%-86%: 14%. The content of leucine, arginine and glycine in the protein composition is high, raw materials are provided for protein synthesis, the anabolic reaction of the protein is promoted, and the grip strength, the step speed and the standing-walking time of a patient suffering from the sarcopenia syndrome are improved.

Description

Technical Field

[0001] The present invention relates to the field of special dietary foods, and in particular to a protein composition, a preparation method and application thereof for special dietary formula foods for sarcopenia syndrome. Background Art

[0002] As people age, their activity levels decrease, and their muscles gradually degenerate. Muscle mass begins to decrease after the age of 40, and decreases by an average of 1% to 2% per year after the age of 50, while muscle strength decreases more significantly. The occurrence of sarcopenia is the result of multiple factors during the aging process, including decreased sex hormone secretion, myocyte apoptosis, mitochondrial dysfunction, and neurodegenerative diseases. Malnutrition or malabsorption are also important causes of its occurrence and development. Skeletal muscle is the body's protein bank, and 60% of the body's protein is stored in skeletal muscle in various forms. Therefore, promoting protein synthesis in the body is an important measure to treat sarcopenia.

[0003] Reduced protein synthesis and increased protein decomposition in the elderly can easily lead to negative nitrogen balance, so adequate protein supplementation is beneficial to reduce the incidence of sarcopenia. Insufficient protein intake will affect the metabolism and physiological regulation of the elderly, including muscle mass damage and decreased muscle strength. Dietary protein can provide the amino acids needed for protein synthesis. For the elderly, a major concern is that the anabolic response of protein may be weakened. The elderly need more protein to maintain nitrogen balance to prevent loss of muscle mass and muscle strength.

[0004] At present, the design of complete nutritional formula food for sarcopenia syndrome mainly focuses on protein supplementation, but how to choose protein and how to mix protein are of great significance for the prevention and treatment of sarcopenia syndrome. By optimizing the reasonable protein composition, a more reasonable protein composition can be provided for patients with sarcopenia syndrome. At present, the choice of protein in China is relatively single, and how to prepare a protein formula food for sarcopenia syndrome is a technical problem to be solved in this field. Summary of the invention

[0005] In view of the problems and shortcomings of the related technologies, the present invention aims to provide a protein composition, a preparation method and an application for use in special dietary foods for sarcopenia. The protein composition can provide good nutritional support for patients with sarcopenia. The preparation method of the present invention has the advantages of simple operation, high efficiency and balanced nutrition.

[0006] In one aspect, the present invention provides a protein composition for use in a medical formula food for sarcopenia syndrome, wherein the protein composition is calculated by weight percentage: Concentrated whey protein: 20% to 50%; Nutritional protein: supplement to 100%; The nutritional protein is a protein mixture consisting of two or more of isolated whey protein, hydrolyzed whey protein, collagen peptides and branched-chain amino acids.

[0007] Preferably, the composition consists of whey protein concentrate, whey protein isolate, whey protein hydrolysate, collagen peptides and branched chain amino acids.

[0008] Preferably, the nutritional protein comprises, by mass percentage, 20%-50% concentrated whey protein, 20%-50% isolated whey protein, 5-15% hydrolyzed whey protein, 10%-20% collagen peptides, and 3%-5% branched-chain amino acids.

[0009] Preferably, the nutritional protein comprises, by mass percentage, 30% concentrated whey protein, 45% isolated whey protein, 10% hydrolyzed whey protein, 10% collagen peptides, and 5% branched-chain amino acids.

[0010] Preferably, the ratio of branched-chain amino acids leucine:isoleucine:valine is 2:1:1.

[0011] Preferably, the amino acid composition is as follows: leucine content is 12.2%, the total content of arginine and glycine is 8.0%, and essential amino acids are 46.6%.

[0012] In the implementation case of the present invention, the sarcopenia syndrome includes primary sarcopenia, secondary sarcopenia or nutrition-related sarcopenia.

[0013] On the other hand, the present invention provides a method for preparing a protein composition for a medical formula food for sarcopenia syndrome, comprising a material mixing step. In one implementation case, the material mixing adopts a gradient mixing method, and the steps include sequentially adding branched-chain amino acids, collagen peptides, hydrolyzed whey protein, isolated whey protein and concentrated whey protein.

[0014] In yet another aspect, the present invention provides a food for special dietary use, comprising the composition of the present invention. In addition to the composition of the present invention, the food may also contain other ingredients, such as creatine, vitamins, minerals, and the like.

[0015] Compared with the prior art, the beneficial effects of the present invention at least include: 1. The present invention adopts different whey proteins, collagen peptides and branched-chain amino acids as gradient protein combinations. All proteins are animal proteins, which are absorbed in a gradient manner to prevent negative nitrogen balance.

[0016] 2. The protein composition of the present invention has a high content of essential amino acids, especially high content of leucine, arginine and glycine; at the same time, whey protein has a high digestibility and utilization rate, which is more conducive to promoting protein anabolism.

[0017] 3. The composition of the present invention can effectively assist in the treatment of patients with sarcopenia. After intervention, the test subjects showed significant improvements in grip strength, gait speed and stand-and-go timing, and the male skeletal muscle mass index exceeded the low muscle mass critical value. Implementation

[0018] The present invention is further explained below in conjunction with specific examples. The present invention is implemented according to the technical solution of the invention, and detailed implementation methods and operating steps are given, but the protection scope of the present invention is not limited to the following examples. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions.

[0019] Unless otherwise specified, the raw materials used in the embodiments of the present invention can be purchased from the market.

[0020] The essential amino acids involved in the present invention are: lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine, and valine.

[0021] The composition of the present invention can be obtained by a preparation method comprising a material mixing step, wherein the material mixing step comprises sequentially adding branched-chain amino acids, collagen peptides, hydrolyzed whey protein, isolated whey protein and concentrated whey protein.

[0022] The composition of the present invention can be used to treat or prevent sarcopenia. The use of the composition in preparing a food for treating or preventing sarcopenia is provided. In one embodiment, the composition of the present invention can improve the limb muscle content and trunk muscle content of people with sarcopenia. In one embodiment, the composition of the present invention can be combined with exercise intervention to treat sarcopenia in the elderly, which can significantly improve the patient's muscle mass, muscle strength and muscle function, and improve the clinical treatment effect.

[0023] Treatment of sarcopenia in my country Exercise therapy Exercise therapy is one of the effective means to prevent and treat sarcopenia syndrome. The mechanisms by which exercise has a beneficial effect on muscles are multifaceted. Aerobic and resistance training cause muscle structural damage and the subsequent release of inflammatory cytokines and growth factors, such as insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF), and mechano-growth factor (MGF), which stimulate the differentiation and proliferation of satellite cells. New nuclei from satellite cells are incorporated into existing muscle fibers, which easily increase the number of "myonuclear domains" and thus increase the cross-sectional area of ​​muscle fibers. Studies have shown that 2 to 3 times of appropriate intensity resistance training per week can improve the physiological and balance functions and walking speed of the elderly. However, due to the actual situation of the elderly, such as stroke, long-term bed rest, and inconvenience in mobility, this method is not feasible, and it is difficult to persist in the long term, and the elderly have low compliance; in addition, there are some exercise contraindications, such as hypoglycemia during resistance training, inconsistent respiratory rhythm during exercise, hypertension, etc., and the occurrence of cardiovascular accidents caused by exercise.

[0024] Prescription medication Age-related hormone reduction is closely related to muscle atrophy and weakness in the elderly. Hormone replacement therapy or other anabolic factor therapy has received a lot of attention as a means to combat aging-related muscle atrophy. Commonly used drugs are testosterone, estrogen, androgen, thyroid hormone and growth hormone. These drugs can improve muscle therapy, maintain the body's lean body mass, and at the same time improve skeletal muscle strength to a certain extent. However, the existing drug treatment effects are not ideal, and they cannot effectively resist muscle loss caused by aging. In addition, these drugs have not been fully confirmed in terms of effectiveness and safety, and long-term use will have side effects. Pharmacological treatment has not yet found a safe and effective drug.

[0025] Nutritional intervention According to statistics, about 2 / 3 of the elderly are at risk of malnutrition. Although exercise intervention can effectively control muscle damage in the elderly, the effect is not obvious for the elderly with severe muscle loss and insufficient protein intake. Insufficient protein intake will affect the metabolism and physiological regulation ability of the elderly, including muscle mass damage and decreased muscle strength. In terms of the quality of protein intake, two key factors need to be considered: one is the content of essential amino acids in protein, especially leucine; the other is the digestibility and utilization of protein. Protein with high digestibility and utilization is more conducive to promoting anabolism. At present, the effectiveness of protein intake of 1.4 g / (kg·d) or more in preventing sarcopenia has been certified, which can offset the decline in protein synthesis rate.

[0026] The determination of the amino acid composition involved in the embodiments of the present invention is carried out with reference to "GB 5009.124-2016 National Food Safety Standard Determination of Amino Acids in Food".

[0027] Table 1 Protein and amino acid content of different proteins and protein hydrolysates name protein Leucine Glycine Arginine Essential amino acids (mg / g protein) Whey Protein Concentrate 75 g / 100 g 103 mg / g 18 mg / g 25 mg / g 462 mg / g Whey Protein Isolate 90 g / 100 g 115 mg / g 17 mg / g 22 mg / g 497 mg / g Hydrolyzed Whey Protein 78 g / 100g 93 mg / g 19 mg / g 25 mg / g 391 mg / g Collagen Peptides 95 g / 100 g 35.3 mg / g 286 mg / g 87 mg / g 135 mg / g Branched Chain Amino Acids 98 g / 100g 490 mg / g / / 1000 mg / g Example

[0028] The protein composition used in the special dietary formula food for sarcopenia syndrome comprises the following raw materials in percentage by weight: 40% of concentrated whey protein, 40% of isolated whey protein, 10% of collagen peptide, 5% of hydrolyzed whey protein and 5% of branched-chain amino acids.

[0029] At room temperature, various materials are added into a three-dimensional mixer according to mass proportion. The material mixing step includes sequentially adding branched-chain amino acids, collagen peptides, hydrolyzed whey protein, isolated whey protein and concentrated whey protein and mixing them. The mixing time is 30 min, the mixing speed is 30 rpm, and the protein composition is obtained after the mixing is completed.

[0030] The amino acid composition content of the protein composition was detected, and the results are shown in Table 2.

[0031] Table 2 Formula of Composition 1 (per bag)

[0032] The ratio of complete protein (concentrated whey protein + isolated whey protein + partially hydrolyzed whey protein) and protein hydrolyzate (partially hydrolyzed whey protein + collagen peptides + branched-chain amino acids) in the combination is 86%:14%, that is, every 12 g of the composition contains 8.62 g of complete protein and 1.4 g of protein hydrolyzate. The total amount of glycine and arginine is 0.578 g, and the content of leucine is 1.264 g. Example

[0033] The protein composition used in a special dietary formula food for sarcopenia syndrome comprises the following raw materials in percentage by weight: 30% of concentrated whey protein, 45% of isolated whey protein, 10% of collagen peptides, 10% of hydrolyzed whey protein and 5% of branched-chain amino acids.

[0034] At room temperature, various materials are added into a three-dimensional mixer according to mass proportion. The material mixing step includes sequentially adding branched-chain amino acids, collagen peptides, hydrolyzed whey protein, concentrated whey protein and isolated whey protein and mixing them. The mixing time is 30 min, the mixing speed is 30 rpm, and the protein composition is obtained after the mixing is completed.

[0035] The amino acid composition content of the protein composition was detected, and the results are shown in Table 3.

[0036] Table 3 Formula of Composition 2 (per bag)

[0037] The ratio of complete protein (concentrated whey protein + isolated whey protein + partially hydrolyzed whey protein) and protein hydrolyzate (partially hydrolyzed whey protein + collagen peptide + branched-chain amino acids) in the combination is 80.7%:19.3%, that is, every 12 g of the composition contains 8.26 g of complete protein and 1.97 g of protein hydrolyzate. The total amount of glycine and arginine is 0.817 g, and the content of leucine is 1.252 g. Example

[0038] The protein composition used in the special dietary formula food for sarcopenia syndrome comprises the following raw materials in percentage by weight: 50% of concentrated whey protein, 30% of isolated whey protein, 12% of collagen peptides, 5% of hydrolyzed whey protein and 3% of branched-chain amino acids.

[0039] At room temperature, various materials are added into a three-dimensional mixer according to mass proportion. The material mixing step includes sequentially adding branched-chain amino acids, hydrolyzed whey protein, collagen peptides, isolated whey protein and concentrated whey protein and mixing them. The mixing time is 30 min, the mixing speed is 30 rpm, and the protein composition is obtained after the mixing is completed.

[0040] The amino acid composition content of the protein composition was detected, and the results are shown in Table 4.

[0041] Table 4 Formula of Composition 3 (per bag)

[0042] Table 4 Formula of Composition 3 (per bag) The ratio of complete protein (concentrated whey protein + isolated whey protein + partially hydrolyzed whey protein) and protein hydrolyzate (partially hydrolyzed whey protein + collagen peptide + branched-chain amino acids) in the combination is 81.6%:18.4%, that is, every 12 g of the composition contains 8.1 g of complete protein and 1.83 g of protein hydrolyzate. The sum of glycine and arginine is 0.906 g, and the content of leucine is 1.101 g. Example

[0043] The protein composition used in the special dietary formula food for sarcopenia syndrome comprises the following raw materials in percentage by weight: 30% of concentrated whey protein, 30% of isolated whey protein, 20% of collagen peptides, 15% of hydrolyzed whey protein and 5% of branched-chain amino acids.

[0044] At room temperature, various materials are added into a three-dimensional mixer according to mass proportion. The material mixing step includes sequentially adding branched-chain amino acids, hydrolyzed whey protein, collagen peptides, isolated whey protein and concentrated whey protein and mixing them. The mixing time is 30 min, the mixing speed is 30 rpm, and the protein composition is obtained after the mixing is completed.

[0045] The amino acid composition content of the protein composition was detected, and the results are shown in Table 5.

[0046] Table 5 Formula of Composition 4 (per bag)

[0047] The ratio of complete protein (whey protein concentrate + whey protein isolate + partially hydrolyzed whey protein) and protein hydrolyzate (partially hydrolyzed whey protein + collagen peptide + branched-chain amino acids) in the combination is 81.6%:18.4%, that is, every 12 g of the composition contains 8.1 g of complete protein and 1.83 g of protein hydrolyzate. The total amount of glycine and arginine is 1.219 g, and the content of leucine is 1.101 g.

[0048] 1. Selection of experimental subjects 60 patients with sarcopenia in the elderly were selected, including 30 males and 30 females. All of them met the inclusion criteria of this study: ① Age ≥ 65 years old, meeting the criteria of "reduced muscle strength" and "reduced muscle mass" in the diagnosis of sarcopenia; ② Stable health and able to move independently; ③ Voluntary participation and filling out the consent form. According to the random number table, they were divided into three groups: resistance training + composition (composition of Example 2) group, resistance training + placebo group (equal amount of maltodextrin), and resistance training group. There was no statistically significant difference in the basic information, self-health evaluation, living habits, functional status and dietary intake of the three groups of patients (all P>0.05).

[0049] Resistance training: The resistance training prescription is 3 times / week, 3 sets / time, 10 times / set, using an intensity of 40% 1RM.

[0050] Resistance training + composition group: On the basis of resistance training, the protein composition (the composition of Example 2) was administered, twice a day, 12 g each time, for 3 months of intervention.

[0051] Resistance training + placebo group: On the basis of resistance training, placebo (maltodextrin) was given, twice a day, 12g each time, for 3 months.

[0052] 2. Observation indicators Physical fitness, muscle mass, muscle strength, and physical activity were measured before and after the intervention. ① Body weight: measure body weight every morning on an empty stomach and without shoes, with the data accurate to 0.1 kg; ② Calf circumference: bend the knee joint to 90°, relax the ankle and leg muscles, and measure the thickest part of the calf; ③ Grip strength: the test subject stands, relaxes, lets the arm hang naturally, holds the handgrip dynamometer in one hand, and squeezes the handgrip dynamometer tightly at one time. Note that during the test, do not let the arm touch the body or shake the handgrip dynamometer; measure 4 times, 2 times for each arm, and take the highest value of the 4 experiments; ④ Walking speed: the venue reserves 2 m at both ends and a normal straight-line distance of 8 m. The test subject completes the test at the usual walking speed, and the walking time of 4 m between the two times is recorded; ⑤ Stand-up-walk timing test: the subject sits at 2 / 3 of the chair, keeps the upper body upright, the back against the chair back, the hands are flat on the thighs, the feet are on the ground, and the toes are facing forward; start timing when leaving the chair back, and require the subject to walk at the safest and fastest speed, bypass the marker 3 m away, and return to the chair when the time ends, and record the time to complete the test. ⑥Skeletal muscle mass index (SMI): The BIA method was used to measure the skeletal muscle mass (ASM) of the limbs, and the square of the height (Ht2) was used for correction, that is, ASM / Ht2 to quantify the muscle mass.

[0053] Table 6 Related indicators of the three groups of subjects before and after the intervention Note: *Compared with before intervention, p<0.05; **Compared with before intervention, p<0.01.

[0054] As can be seen from Table 6, there was no significant change in body weight, calf circumference and skeletal muscle mass index among the six groups of test subjects before and after the intervention, but the skeletal muscle index of the male test subjects in the resistance training + combination group increased from 5.41 kg / m2 to 7.21 kg / m2, which was greater than the low muscle mass critical value proposed by EWGSOP2 (7.0 kg / m2 for men); the resistance training + combination group had significant differences in grip strength, walking speed and stand-and-walk test compared with the resistance training group and the resistance training + placebo group, indicating that the protein composition of Example 2 can improve the grip strength, walking speed and stand-and-walk time of patients with sarcopenia. It is recommended that patients with sarcopenia appropriately supplement the protein composition of Example 2 on the basis of diet and resistance training.

[0055] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A protein composition for muscle wasting syndrome. The protein composition comprises intact protein, protein hydrolysate and free amino acids, wherein the leucine content is more than 10 wt%, the total content of arginine and glycine is more than 5 wt%, the essential amino acid content is more than 40 wt%, and the ratio of the classified intact protein to the protein hydrolysate is 80.7%:19.3%-86%:14%.

2. The composition of claim 1, wherein the leucine content is 10 wt%-14 wt%, the total content of arginine and glycine is above 5 wt%, and the essential amino acid content is 40 wt%-50 wt%.

3. The composition of claim 1, wherein the intact protein is selected from the group consisting of animal proteins, including whey protein concentrate and whey protein isolate.

4. The composition of claim 1, wherein the protein hydrolysate comprises collagen peptides and hydrolyzed whey protein.

5. The composition of claim 1, wherein the hydrolyzed whey protein has a degree of hydrolysis of 23% to 29%.

6. The composition of claim 1, wherein the free amino acids are branched chain amino acids.

7. The composition of claim 6, wherein the branched chain amino acids ratio of leucine:isoleucine:valine is 2:1:

1.

8. The composition of claim 1, wherein the composition consists of concentrated whey protein, isolated whey protein, hydrolyzed whey protein, collagen peptides and branched-chain amino acids, and the composition consists of 20%-50% concentrated whey protein, 20%-50% isolated whey protein, 5-15% hydrolyzed whey protein, 10%-20% collagen peptides, and 3%-5% branched-chain amino acids by weight.

9. A method for preparing the composition of any one of claims 1 to 7, comprising a material mixing step, preferably the material mixing step comprises sequentially adding branched-chain amino acids, hydrolyzed whey protein, collagen peptides, isolated whey protein and concentrated whey protein.

10. Use of the composition according to any one of claims 1 to 7 in a protein composition in the form of food, including milk powder or special dietary food.

Images